Drug-Coated Balloons Reduce the Need for Permanent Heart Stents

Why It Matters

If drug‑coated balloons can reliably replace permanent stents, hospitals could lower complication rates and expand treatment options for acute coronary syndrome patients.

Key Takeaways

• SEB matched DES in one-year TVF rates (5.3% vs 4.9%).
• Cardiac death similar between SEB and DES (0.6% vs 0.8%).
• Minimal stenting reduces permanent metal exposure in arteries.
• Study enrolled 1,089 NSTEMI or unstable angina patients.
• Longer-term outcomes required to assess SEB durability.

Pulse Analysis

Acute coronary syndrome remains a leading cause of emergency cardiac care, with NSTEMI accounting for roughly 70% of heart attacks. The standard percutaneous coronary intervention relies on drug‑eluting stents that permanently scaffold the artery, but the metal framework can provoke chronic inflammation, restenosis, or late thrombosis in up to 4% of cases annually. Over the past decade, drug‑coated balloons have emerged as a potential alternative, delivering antiproliferative medication without leaving a permanent implant, yet robust comparative data in real‑world ACS populations have been limited.

The SELUTION DeNovo sub‑study, presented at the 2026 SCAI and CAIC‑ACCI summit, directly addressed that gap by randomizing 1,089 patients with NSTEMI or unstable angina to either a sirolimus‑eluting balloon (SEB) with provisional stenting or a conventional DES. At one year, the SEB cohort achieved a target‑vessel failure rate of 5.3% versus 4.9% for DES, and cardiac mortality was virtually identical (0.6% vs 0.8%). Rates of target‑vessel myocardial infarction and clinically driven revascularization also mirrored those of the stent arm, suggesting that the balloon strategy does not compromise efficacy while eliminating permanent metal exposure.

For interventional cardiologists, these results could shift procedural decision‑making toward a more conservative, “leave‑nothing‑behind” philosophy, especially in lesions amenable to balloon angioplasty. Hospitals may see reduced long‑term costs associated with stent‑related complications and greater flexibility for future interventions. However, the durability of the SEB approach beyond the first year remains unknown, prompting the need for five‑year follow‑up data. If longer‑term outcomes confirm the early safety signal, drug‑coated balloons could become a mainstream option, reshaping the device market and influencing guideline recommendations for ACS management.